News | September 17, 2025
Lilly to build $5 billion manufacturing facility in Virginia
This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year
This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research
His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors
First pivotal Phase 3 trial to show superiority of Keytruda plus a TROP2 antibody-drug conjugate, Trodelvy, versus standard of care in first-line metastatic TNBC
Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs
Subscribe To Our Newsletter & Stay Updated
